(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 59.17% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Arcturus Therapeutics Holdings's revenue in 2024 is $124,526,000.On average, 3 Wall Street analysts forecast ARCT's revenue for 2024 to be $4,310,142,501, with the lowest ARCT revenue forecast at $3,016,903,149, and the highest ARCT revenue forecast at $5,025,397,936. On average, 3 Wall Street analysts forecast ARCT's revenue for 2025 to be $8,280,351,495, with the lowest ARCT revenue forecast at $4,508,926,309, and the highest ARCT revenue forecast at $13,733,857,737.
In 2026, ARCT is forecast to generate $13,904,847,900 in revenue, with the lowest revenue forecast at $3,752,680,635 and the highest revenue forecast at $24,057,015,165.